# Petrichor Healthcare Capital Management

Petrichor Healthcare Capital Management is a Private Equity based in New York, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** 220 East 42nd Street, 37th / PH Floor, New York, NY 10017, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** www.petrichorcap.com
- **LinkedIn:** https://www.linkedin.com/company/petrichor-capital

## Regulatory record

- **CRD number:** 288664
- **SEC file number:** 801-112209
- **Registration status:** APPROVED
- **Latest Form ADV filing:** 2026-03-31T05:00:00.000Z
- **Reports private funds:** Yes
- **Private funds reported:** 0
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/288664

## About

Petrichor Healthcare Capital Management is an SEC-registered investment adviser in NEW YORK, NY, registered since 2018. The firm manages approximately $966 million in assets. It has 16 employees and 12 investment advisers.

## Sectors

- Healthcare Services
- Digital Health

## People

- Tadd Wessel — Founder and Managing Partner
- Patrick Lally — Partner
- Michael Beecham — Partner
- Samuel Hall — Founder, Managing Partner Scion
- Aaron Kantoff — Founder, Managing Partner Scion

## Questions

### Who runs investment decisions at Petrichor Healthcare Capital Management?

Managing Partner Tadd Wessel leads the firm. He is supported by Partners Patrick Lally and Michael Beecham within Petrichor Capital Partners. For the Scion Life Sciences vehicle, Samuel Hall and Aaron Kantoff serve as founding managing partners and drive venture-creation decisions. The firm's website emphasizes a collaborative model built on deep scientific and commercial expertise across its leadership.

### How is Petrichor's Scion Life Sciences different from its main fund?

Scion Life Sciences is a dedicated venture capital fund for founding and building new biotechnology companies. It seeks clinically transformative or curative medicines and explicitly avoids incremental advances. Petrichor Capital Partners, by contrast, invests across private and public companies in biopharma, medical technology, and services at later development and commercial stages.

### What investment stages does Petrichor typically target?

Petrichor's platform spans company formation through late-stage growth. Scion Life Sciences handles the earliest stage — company creation. Petrichor Capital Partners covers expansion, late-stage, and commercial growth, including public-company investments. The firm's website confirms this full lifecycle approach but does not break out a minimum or maximum check size.

### How does Petrichor source proprietary deal flow?

Petrichor relies on its in-house team of scientists, physicians, and operators to identify opportunities rather than a traditional agent-driven origination model. By embedding expertise in biopharmaceutical product development, regulatory pathways, and medical technology commercialization, the firm aims to spot and create investment opportunities before they are broadly marketed to other funds.

### Does Petrichor participate in fund commitments or only direct deals?

The firm does not publicly describe itself as a fund-of-funds. Its disclosed vehicles — Petrichor Capital Partners and Scion Life Sciences — both appear to execute direct investments and company formation. There is no reference to investing in third-party funds, though a lack of detailed portfolio disclosures makes it difficult to rule out co-investment alongside other managers.

## Related profiles

- [Petri](https://altss.com/profile/petri)
- [PetroCap](https://altss.com/profile/petrocap)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/petrichor-healthcare-capital-management

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology